RCT: Ranolazine shows benefit for persistent angina in patients with type 2 diabetes

Source: Journal of the American College of Cardiology Area: News According to data presented at the American Society of Cardiology annual meeting, and published early online in the Journal of the American College of Cardiology, ranolazine reduced episodes of chest pain in patients with diabetes.   Researchers examined the efficacy of ranolazine versus placebo on weekly angina frequency in patients with type 2 diabetes, coronary artery disease (CAD), and chronic stable angina who remain symptomatic despite treatment with up to 2 anti-anginal agents.   The trial, Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) was a randomised, double-blind, placebo-controlled trial in which patients were randomised to twice daily placebo (n=465) or ranolazine 500mg bd (increased to 100mg bd if appropriate) for 8 weeks (n=462). Anginal episodes and nitroglycerin use were recorded with daily entry into a novel electronic diary. Primary outcome was the average weekly number of anginal episodes over the ...
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news